Imiquimod-Induced Psoriasis Efficacy Studies

JAX offers preclinical imiquimod-induced psoriasis mouse models as a rapid screening approach for candidate psoriatic therapies.

Learn More

Imiquimod (IMQ) is a toll-like receptor agonist that acts as an immune response modifier. Topical application of IMQ to the skin of susceptible BALB/cJ and C57BL/6J mice induces inflammation with features commonly found in human psoriatic skin, including erythema and scaling. The advantage of this model over other inducible psoriasis models is the fast induction of clinical phenotypes for rapid therapeutic screening.

Phenotype BALB/cJ(JR# 000651) C57BL/6J(JR# 000664) Method
Clinical Observations PASI Scoring & Digital Images
Skin Histopathology H&E Staining and Semi-Quantitative Scoring
Phenotyping Skin Resident Lymphocytes Flow Cytometry
PBMC/Spleen/Lymph Node Phenotyping Flow Cytometry
Serum Cytokines Meso Scale Discovery

Standard psoriasis study designs

Example study design:
  • 6-8 week old female BALB/cJ
  • Scaling & Lesion Scores and Erythema Scores measure daily
  • Histopathological evaluation of the skin
Timeline Imiquimod

Representative Data

Prophylactic Study 1 Prophylactic Study 2

Figure 1. IMQ-induced skin psoriasis and inflammation in mice. BALB/cJ mice were treated daily for 6 days with IMQ cream of control (petroleum jelly) on the shaved back skin and received either cyclosporine A + glucosamine or vehicle. Cyclosporine A + glucosamine reduced the Scaling and Lesion severity score as well as the Erythema score compared to vehicle-treated mice.

Examples of Imiquimod

Figure 2. Histopathological evaluation in skin from Imiquimod-induced psoriasis. H&E staining showed that IMQ applied to the skin of BALBc/J mice resulted in vasodilation, infiltration of inflammatory cells in epidermis and dermis, increased epidermal thickening, and increased keratinocyte differentiation compared with the control (petroleum jelly-treated group).